Sanofi Pasteur, the vaccines arm of Sanofi, announced the launch of an innovative ready-to-use fully liquid 6-in-1 vaccine, Hexaxim, in India. The vaccine, indicated for primary and booster vaccination of infants and toddlers from six weeks to 24 months of age, provides protection against six major childhood diseases - diphtheria, tetanus, pertussis (whooping cough), polio, Haemophilus influenza B and hepatitis B.
The burden of these six diseases is significant, particularly in infants. Consequently, WHO and wide majority of countries around the world recommend vaccination against these diseases. India, under the Universal Immunization Program, also offers protection against these diseases.
Globally, Hexaxim is the only combination vaccine with acellular pertussis (acP) and inactivated poliovirus vaccine (IPV) to have received a prequalification by the WHO, a company statement says.
Jean-Pierre Baylet, country head Sanofi Pasteur India, Nepal and Sri Lanka, said, "Given the large influx of patients met by pediatricians in India, Hexaxim will offer convenience and ensure consistency in administering the right dose of each antigen every single time".
Hexaxim, during its clinical study assessment, was found to be safe and well tolerated as a primary series and booster vaccination in all schedules, countries, and ethnicities tested, it added.
The burden of these six diseases is significant, particularly in infants. Consequently, WHO and wide majority of countries around the world recommend vaccination against these diseases. India, under the Universal Immunization Program, also offers protection against these diseases.
Globally, Hexaxim is the only combination vaccine with acellular pertussis (acP) and inactivated poliovirus vaccine (IPV) to have received a prequalification by the WHO, a company statement says.
Jean-Pierre Baylet, country head Sanofi Pasteur India, Nepal and Sri Lanka, said, "Given the large influx of patients met by pediatricians in India, Hexaxim will offer convenience and ensure consistency in administering the right dose of each antigen every single time".
Hexaxim, during its clinical study assessment, was found to be safe and well tolerated as a primary series and booster vaccination in all schedules, countries, and ethnicities tested, it added.